Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca Purchase Aims At Triglycerides

by Lisa M. Jarvis
June 3, 2013 | A version of this story appeared in Volume 91, Issue 22

In its latest bid to bolster its late-stage pipeline, AstraZeneca is acquiring Princeton, N.J.-based Omthera Pharmaceuticals. With the deal, AstraZeneca gains Epanova, an omega-3 free-fatty-acid composition in development to lower triglyceride levels. Omthera plans to file a New Drug Application for Epanova this year. AstraZeneca expects to pursue other indications, including a fixed-dose combination with its cholesterol-lowering drug Crestor. AstraZeneca will pay about $260 million for Omthera and could pay another $120 million in milestones related to the launch of Epanova.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.